An exploratory, open-label phase Ib study of RNActive derived cancer vaccine and local radiation as consolidation and maintenance treatment in patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor